2024
Provider Experience With the Use of Ketamine for Refractory Status Epilepticus
Tantillo G, Davis N, Granstein J, Yoo J, Agarwal P, Reilly K, Reynolds A, Kayal G, Liang J, Jetté N. Provider Experience With the Use of Ketamine for Refractory Status Epilepticus. Clinical Neuropharmacology 2024, 47: 37-43. PMID: 38478363, DOI: 10.1097/wnf.0000000000000582.Peer-Reviewed Original ResearchConceptsRefractory status epilepticusStatus epilepticusPerceived contraindicationsUse of vasopressorsFirst-line agentsRefractory status epilepticus treatmentSecond-line agentsAssociated with complicationsElevated intracranial pressureNeurocritical Care SocietyRespiratory depressionHeart failureEEG monitoringHemodynamic supportOptimal doseKetamine useSeizure controlIntracranial pressureControl seizuresDecreased needKetamine usersAmerican Epilepsy SocietyKetamineAmerican AcademyAnesthetic agents
2023
How do smoking, vaping, and nicotine affect people with epilepsy and seizures? A scoping review protocol
Narrett J, Khan W, Funaro M, Moeller J. How do smoking, vaping, and nicotine affect people with epilepsy and seizures? A scoping review protocol. PLOS ONE 2023, 18: e0288120. PMID: 37418386, PMCID: PMC10328254, DOI: 10.1371/journal.pone.0288120.Peer-Reviewed Original ResearchConceptsSmoking cessationTobacco useReview protocolBurden of comorbiditiesType of epilepsyJoanna Briggs Institute ManualPopulation of personsPeer-reviewed journalsSeizure frequencyNicotine replacementControl seizuresPreventable deathsSide effectsSmokingEthical approvalEpilepsyHealth outcomesPrevalent diseaseSeizuresPersonalized careDirect further researchEvidence synthesisMajor causeSystematic screeningAPA PsycInfo
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply